Overview

Comparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL.

Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
Multicentric randomized phase III study comparing high doses of chemotherapy with Rituximab followed by auto-transplant HPC versus CHOP plus Rituximab as first line therapy in high risk patients with DLBCL Non-Hodgkin's lymphomas.
Phase:
Phase 3
Details
Lead Sponsor:
Gruppo Italiano Terapie Innovative nei Linfomi
Treatments:
Rituximab